Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.
Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.
Overview
GLP-1 drugs are more popular than ever. This week, polling organization Gallup reported that 11% of U.S. adults are currently taking GLP-1 medications for weight loss, which is a huge jump from the 3% who said they were using the drugs in 2024. And 15% of those polled said they've used the drugs at some point, which is an increase of 9 percentage points over 2024.
Moreover, about 9 in 10 Americans are aware that the drugs are available for weight loss, up from 8 in 10 in 2024. That's good news for makers of the GLP-1 drugs, including Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), which make the best-selling GLP-1 weight loss drugs.
Details
But Lilly has to be considered the biggest beneficiary, as its drug tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, became the world's best-selling drug late last year, surpassing Keytruda, a cancer treatment manufactured by Merck. Lilly reported sales of $8.7 billion for Mounjaro in the first quarter and $4.2 billion for Zepbound, for a combined $12.9 billion.
Source
Originally published at www.fool.com.